Lipopolysaccharide Animal Models for Parkinson's Disease
Lipopolysaccharide (LPS), an endotoxin from Gram-negative bacteria, acts as a potent stimulator of microglia and has been used to study the inflammatory process in the pathogenesis of Parkinson's disease (PD) and anti-inflammatory therapy for PD treatment. Here, we review the growing body of li...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Parkinson's Disease |
| Online Access: | http://dx.doi.org/10.4061/2011/327089 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850216342020423680 |
|---|---|
| author | Mei Liu Guoying Bing |
| author_facet | Mei Liu Guoying Bing |
| author_sort | Mei Liu |
| collection | DOAJ |
| description | Lipopolysaccharide (LPS), an endotoxin from Gram-negative bacteria, acts as a potent stimulator of microglia and has been used to study the inflammatory process in the pathogenesis of Parkinson's disease (PD) and anti-inflammatory therapy for PD treatment. Here, we review the growing body of literature on both in vitro and in vivo LPS PD models. Primary cell cultures from mesencephalic tissue were exposed to LPS in vitro; LPS was stereotaxically injected into the substantia nigra, striatum, or globus pallidus of brain or injected into the peritoneal cavity of the animal in vivo. In conclusion, the LPS PD models are summarized as (1) local and direct LPS treatment and (2) systemic LPS treatment. Mechanisms underlying the PD models are investigated and indicated that LPS induces microglial activation to release a variety of neurotoxic factors, and damaged neurons may trigger reactive microgliosis, which lead to progressive dopaminergic neurodegeneration. |
| format | Article |
| id | doaj-art-3e8358d8b6c5438f9d969a8fd605f458 |
| institution | OA Journals |
| issn | 2042-0080 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Parkinson's Disease |
| spelling | doaj-art-3e8358d8b6c5438f9d969a8fd605f4582025-08-20T02:08:20ZengWileyParkinson's Disease2042-00802011-01-01201110.4061/2011/327089327089Lipopolysaccharide Animal Models for Parkinson's DiseaseMei Liu0Guoying Bing1Department of Anatomy and Neurobiology, College of Medicine, University of Kentucky, Lexington, KY 40536, USADepartment of Anatomy and Neurobiology, College of Medicine, University of Kentucky, Lexington, KY 40536, USALipopolysaccharide (LPS), an endotoxin from Gram-negative bacteria, acts as a potent stimulator of microglia and has been used to study the inflammatory process in the pathogenesis of Parkinson's disease (PD) and anti-inflammatory therapy for PD treatment. Here, we review the growing body of literature on both in vitro and in vivo LPS PD models. Primary cell cultures from mesencephalic tissue were exposed to LPS in vitro; LPS was stereotaxically injected into the substantia nigra, striatum, or globus pallidus of brain or injected into the peritoneal cavity of the animal in vivo. In conclusion, the LPS PD models are summarized as (1) local and direct LPS treatment and (2) systemic LPS treatment. Mechanisms underlying the PD models are investigated and indicated that LPS induces microglial activation to release a variety of neurotoxic factors, and damaged neurons may trigger reactive microgliosis, which lead to progressive dopaminergic neurodegeneration.http://dx.doi.org/10.4061/2011/327089 |
| spellingShingle | Mei Liu Guoying Bing Lipopolysaccharide Animal Models for Parkinson's Disease Parkinson's Disease |
| title | Lipopolysaccharide Animal Models for Parkinson's Disease |
| title_full | Lipopolysaccharide Animal Models for Parkinson's Disease |
| title_fullStr | Lipopolysaccharide Animal Models for Parkinson's Disease |
| title_full_unstemmed | Lipopolysaccharide Animal Models for Parkinson's Disease |
| title_short | Lipopolysaccharide Animal Models for Parkinson's Disease |
| title_sort | lipopolysaccharide animal models for parkinson s disease |
| url | http://dx.doi.org/10.4061/2011/327089 |
| work_keys_str_mv | AT meiliu lipopolysaccharideanimalmodelsforparkinsonsdisease AT guoyingbing lipopolysaccharideanimalmodelsforparkinsonsdisease |